

REFERENCES

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM, Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu Rev Pharmacol Toxicol* **39**: 361-98, 1999.
2. Gottesman MM, Fojo T and Bates SE, Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer* **2**(1): 48-58, 2002.
3. Lage H, ABC-transporters: implications on drug resistance from microorganisms to human cancers. *Int J Antimicrob Agents* **22**(3): 188-99, 2003.
4. Higgins CF, ABC transporters: from microorganisms to man. *Annu Rev Cell Biol* **8**: 67-113, 1992.
5. Sauna ZE, Smith MM, Muller M, Kerr KM and Ambudkar SV, The mechanism of action of multidrug-resistance-linked P-glycoprotein. *J Bioenerg Biomembr* **33**(6): 481-91, 2001.
6. Litman T, Druley TE, Stein WD and Bates SE, From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. *Cell Mol Life Sci* **58**(7): 931-59, 2001.
7. Ambudkar SV and aZE, Gottesman, M. M and Szakacs G., A novel way to spread drug resistance in tumor cells: Functional intercellular transfer of P-glycoprotein (ABCB1). *Trends Phamacol Sci* **In press**, 2005.
8. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM, P-glycoprotein: from genomics to mechanism. *Oncogene* **22**(47): 7468-85, 2003.
9. Lockhart C TRGaKRB, Phamacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. *Mol Cancer Ther* **2**: 685-698, 2003.
10. Leslie EM, Deeley RG and Cole SP, Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. *Toxicol Appl Pharmacol* **204**(3): 216-37, 2005.
11. Sarkadi B, Ozvegy-Laczka C, Nemet K and Varadi A, ABCG2 -- a transporter for all seasons. *FEBS Lett* **567**(1): 116-20, 2004.
12. Bates SE, Robey R, Miyake K, Rao K, Ross DD and Litman T, The role of half-transporters in multidrug resistance. *J Bioenerg Biomembr* **33**(6): 503-11, 2001.
13. Tsuruo T IH, Tsukagoshi S, Sakurai Y, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res* **41**: 1967-1972, 1981.
14. Green LJ MP, Slapak CA, Modulation by LY335979 of P-glycoprotein function in multidrug resistant cell lines and human natural killer cells. *Biochem Pharmacol* **61**: 1393-1396, 2001.
15. Twentyman PR and N. B, Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. *Eur J Cancer* **7**: 1639-1642, 1991.
16. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH and van Tellingen O, Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. *Clin Cancer Res* **6**(11): 4416-21, 2000.

17. Krishna R ML, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur J Pharm Sci* **11**: 265-283, 2000.
18. Leonard GD, Fojo T and Bates SE, The role of ABC transporters in clinical practice. *Oncologist* **8**(5): 411-24, 2003.
19. Nakano R, Oka M, Nakamura T, Fukuda M, Kawabata S, Terashi K, Tsukamoto K, Noguchi Y, Soda H and Kohno S, A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. *Biochem Biophys Res Commun* **251**(1): 307-12, 1998.
20. Rabindran SK, Ross, D.D., Doyle, L.A. Yang, W., and Green berger, L.M., Fumitrimorgin C reverse multidrug resistance in cells transfected with the breast cancer resistance protein. *Cancer Res* **60**: 47-50, 2000.
21. Rabindran SK, He, H, Singh, M., Brown, E., Collins K.I., Annable, T., and Green berger, L.M., Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. *Cancer Res* **58**: 5850-5858, 1998.
22. He H, Rabindran, S.G., Greenberger, L.M., and Carter, G.T., Fumitremorgin C analogs that reverse mitoxantrone resistance in human colon carcinoma cells. *Med. Chem. Res* **9**: 424-437, 1999.
23. Joe B, Vijaykumar M and Lokesh BR, Biological properties of curcumin-cellular and molecular mechanisms of action. *Crit Rev Food Sci Nutr* **44**(2): 97-111, 2004.
24. Miquel J, Bernd A, Sempere JM, Diaz-Alperi J and Ramirez A, The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. *Arch Gerontol Geriatr* **34**(1): 37-46, 2002.
25. Aggarwal BB, Kumar A and Bharti AC, Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res* **23**(1A): 363-98, 2003.
26. Anuchapreeda S, Effect of turmeric curcuminoids on MDR1 promoter activity and P-glycoprotein function in human cervical carcinoma cells. In: *Biochemistry*. Chiang Mai university, Chiang Mai, 2002.
27. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV and Limtrakul PN, Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. *Biochem Pharmacol* **64**(4): 573-82, 2002.
28. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV and Limtrakul P, Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. *Biochem Pharmacol* **68**(10): 2043-52, 2004.
29. Gottesman MM, Mechanism of cancer drug resistance. *Annu Rev Med* **53**: 615-27, 2002.
30. van Veen HW and Konings WN, The ABC family of multidrug transporters in microorganisms. *Biochim Biophys Acta* **1365**(1-2): 31-6, 1998.
31. Dean M, Rzhetsky A and Allikmets R, The human ATP-binding cassette (ABC) transporter superfamily. *Genome Res* **11**(7): 1156-66, 2001.
32. Klein I, Sarkadi B and Varadi A, An inventory of the human ABC proteins. *Biochim Biophys Acta* **1461**(2): 237-62, 1999.

33. Glavenas Christos K, Cserpes J and Sarkadi B, The role of ABC transporters in Drug resistance, Metabolism and Toxicity. *Curr Drug Del* **1**: 27-42, 2004.
34. Gottesman MM and Ambudkar SV, Overview: ABC transporters and human disease. *J Bioenerg Biomembr* **33**(6): 453-8, 2001.
35. Polgar O and Bates SE, ABC transporters in the balance: is there a role in multidrug resistance? *Biochem Soc Trans* **33**(Pt 1): 241-5, 2005.
36. K D, Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor. *Cancer Chemother* **55**: 133-141, 1971.
37. Juliano RL and Ling V, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta* **455**(1): 152-62, 1976.
38. Schinkel AH, Kemp S, Dolle M, Rudenko G and Wagenaar E, N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. *J Biol Chem* **268**(10): 7474-81, 1993.
39. Zhang X CKaGL, Functional evidence that transmembrane 11 and 12 form part of the drug binding domain in P-glycoprotein encoded by MDR1. *J.Biol.Chem* **270**: 22957-22961, 1995.
40. Urbatsch IL SB, Bhagat S and Senior AE, Both P-glycoprotein nucleotide binding sites are catalytically active. *J.Biol.Chem* **270**: 26956-26961, 1995.
41. Muller M and Bakos E WE, Varadi A and Germann UA, Altered drug stimulated ATPase activity in mutants of the human multidrug resistance protein. *J.Biol.Chem* **271**: 1877-1883, 1996.
42. DM LtaC, Covalent modification of human P-glycoprotein mutants containing a single cystein in either nucleotide binding fold abolishes drug stimulated ATPase activity. *J Biol Chem* **270**: 22957-22961, 1995.
43. Demmer A, Thole H, Kubesch P, Brandt T, Raida M, Fislage R and Tummler B, Localization of the idomycin binding site in hamster P-glycoprotein. *J Biol Chem* **272**(33): 20913-9, 1997.
44. Isenberg B, Thole H, Tummler B and Demmer A, Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein. *Eur J Biochem* **268**(9): 2629-34, 2001.
45. Borst P, Evers R, Kool M and Wijnholds J, The multidrug resistance protein family. *Biochem Biophys Acta* **1461**: 347-357, 1999.
46. Borst P, Evers R, Kool M and Wijnholds J, A family of drug transporters: the multidrug resistance-associated proteins. *J Natl Cancer Inst* **92**(16): 1295-302, 2000.
47. Deeley RG and Cole SP, Function, evolution and structure of multidrug resistance protein (MRP). *Semin Cancer Biol* **8**(3): 193-204, 1997.
48. Yabuuchi H, Takayanagi S, Yoshinaga K, Taniguchi N, Aburatani H and Ishikawa T, ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver. *Biochem Biophys Res Commun* **299**(3): 410-7, 2002.
49. Haimeur A, Conseil G, Deeley RG and Cole SP, The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. *Curr Drug Metab* **5**(1): 21-53, 2004.
50. Gao M, Cui HR, Loe DW, Grant CE, Almquist KC, Cole SP and Deeley RG, Comparison of the functional characteristics of the nucleotide binding

- domains of multidrug resistance protein 1. *J Biol Chem* **275**(17): 13098-108, 2000.
51. Nagata K, Nishitani M, Matsuo M, Kioka N, Amachi T and Ueda K, Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1. *J Biol Chem* **275**(23): 17626-30, 2000.
 52. Keppler D, Kamisako T, Leier I, Cui Y, Nies AT, Tsujii H and Konig J, Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. *Adv Enzyme Regul* **40**: 339-49, 2000.
 53. Renes J, de Vries EG, Jansen PL and Muller M, The (patho)physiological functions of the MRP family. *Drug Resist Updat* **3**(5): 289-302, 2000.
 54. Renes J, de Vries EG, Nienhuis EF, Jansen PL and Muller M, ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. *Br J Pharmacol* **126**(3): 681-8, 1999.
 55. Barnouin K, Leier I, Jedlitschky G, Pourtier-Manzanedo A, Konig J, Lehmann WD and Keppler D, Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. *Br J Cancer* **77**(2): 201-9, 1998.
 56. Ballatori N, Hammond CL, Cunningham JB, Krance SM and Marchan R, Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. *Toxicol Appl Pharmacol* **204**(3): 238-55, 2005.
 57. Hipfner DR, Deeley RG and Cole SP, Structural, mechanistic and clinical aspects of MRP1. *Biochim Biophys Acta* **1461**(2): 359-76, 1999.
 58. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V and Dean M, A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. *Cancer Res* **58**(23): 5337-9, 1998.
 59. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T and Bates SE, Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. *Cancer Res* **59**(1): 8-13, 1999.
 60. Doyle LA and Ross DD, Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). *Oncogene* **22**(47): 7340-58, 2003.
 61. Alqawi O, Bates S and Georges E, Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding. *Biochem J* **382**(Pt 2): 711-6, 2004.
 62. Ejendal KF and Hrycyna CA, Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. *Curr Protein Pept Sci* **3**(5): 503-11, 2002.
 63. J.D MQaU, Role of the breast cancer resistance protein (ABCG2) in drug transport. *AAPSJ* **1**(7): E118-E133, 2005.
 64. Ozvegy-Laczka C, Koblos G, Sarkadi B and Varadi A, Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. *Biochim Biophys Acta* **1668**(1): 53-63, 2005.
 65. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS and Bates SE, Mutations at amino-acid 482 in the ABCG2

- gene affect substrate and antagonist specificity. *Br J Cancer* **89**(10): 1971-8, 2003.
66. Yoshikawa M, Kasamatsu S, Yasunaga M, Wang G, Ikegami Y, Yoshida H, Tarui S, Yabuuchi H and Ishikawa T, Does ABCG2 need a heterodimer partner? Expression and functional evaluation of ABCG2 (Arg 482)*. *Drug Metab Pharmacokinet* **17**(2): 130-5, 2002.
 67. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M and Bates SE, Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. *Cancer Res* **61**(18): 6635-9, 2001.
 68. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y and Sugimoto Y, Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. *Int J Cancer* **107**(5): 757-63, 2003.
 69. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD and Kohno S, Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. *Biochem Biophys Res Commun* **280**(5): 1216-23, 2001.
 70. Mao QaUJD, Role of the breast cancer resistance protein (ABCG2) in drug transport. *AAPS J* **7**(1): E118-E133, 2005.
 71. Ross DD, Novel mechanisms of drug resistance in leukemia. *Leukemia* **14**(3): 467-73, 2000.
 72. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H and Sorrentino BP, The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med* **7**(9): 1028-34, 2001.
 73. Ejendal KF and Hrycyna CA, Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. *Mol Pharmacol* **67**(3): 902-11, 2005.
 74. Leith CP, Kopecky KJ, Chen IM, Eijdem L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR and Willman CL, Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. *Blood* **94**(3): 1086-99, 1999.
 75. Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, Giustolisi GM, Pavone B, Palumbo GA, Di Raimondo F, Milone G, Guglielmo P and Giustolisi R, Multidrug resistance mechanisms in chronic lymphocytic leukaemia. *Br J Haematol* **116**(4): 774-80, 2002.
 76. Nooter K, Burger H and Stoter G, Multidrug resistance-associated protein (MRP) in haematological malignancies. *Leuk Lymphoma* **20**(5-6): 381-7, 1996.
 77. Trock BJ, Leonessa F and Clarke R, Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. *J Natl Cancer Inst* **89**(13): 917-31, 1997.

78. Clifford SC, Neal DE and Lunec J, Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. *Br J Cancer* **73**(5): 659-66, 1996.
79. Tada Y, Wada M, Migita T, Nagayama J, Hinoshita E, Mochida Y, Maehara Y, Tsuneyoshi M, Kuwano M and Naito S, Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. *Int J Cancer* **98**(4): 630-5, 2002.
80. Ren JH, Du XY, Guo XN, Wang Y, Zhang JN, Lin FR and Dong ZR, [Relationship between resistance to chemotherapy and expression of breast cancer resistance protein (BCRP) gene in patients with acute leukemia]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* **12**(1): 55-8, 2004.
81. Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE, Scheffer GL, Scheper RJ, Vellenga E and de Vries EG, The role of breast cancer resistance protein in acute lymphoblastic leukemia. *Clin Cancer Res* **9**(14): 5171-7, 2003.
82. van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der Maas M, Weijers GW, Scheffer GL, Allen JD, Scheper RJ, van Loevezijn A, Ossenkoppele GJ and Schuurhuis GJ, Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. *Haematologica* **88**(2): 134-47, 2003.
83. van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ and de Vries EG, Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. *Blood* **99**(10): 3763-70, 2002.
84. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ and Taylor CG, Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. *Br J Haematol* **115**(2): 257-62, 2001.
85. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D and Ross DD, Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. *Clin Cancer Res* **9**(9): 3320-8, 2003.
86. Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ, Germa-Lluch JR and Izquierdo MA, Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. *J Pathol* **198**(2): 213-9, 2002.
87. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res* **41**(5): 1967-72, 1981.
88. Spoelstra EC, Westerhoff HV, Pinedo HM, Dekker H and Lankelma J, The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. *Eur J Biochem* **221**(1): 363-73, 1994.
89. Chao NJ, Aihara M, Blume KG and Sikic BI, Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human

- leukemic cell lines and normal bone marrow. *Exp Hematol* **18**(11): 1193-8, 1990.
90. Avendano C and Menendez JC, Inhibitors of multidrug resistance to antitumor agents (MDR). *Curr Med Chem* **9**(2): 159-93, 2002.
 91. Atadja P, Watanabe T, Xu H and Cohen D, PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. *Cancer Metastasis Rev* **17**(2): 163-8, 1998.
 92. Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD and Fojo T, A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valsopodar). *Cancer* **92**(6): 1577-90, 2001.
 93. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D and Vickers AE, The multidrug resistance modulator valsopodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. *Drug Metab Dispos* **26**(8): 802-11, 1998.
 94. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J and Harding MW, Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. *Anticancer Drugs* **8**(2): 125-40, 1997.
 95. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW and Charpentier D, A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. *Gynecol Oncol* **86**(3): 302-10, 2002.
 96. Krishna R and Mayer LD, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur J Pharm Sci* **11**(4): 265-83, 2000.
 97. Dantzig AH, Law KL, Cao J and Starling JJ, Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. *Curr Med Chem* **8**(1): 39-50, 2001.
 98. Shepard RL, Cao J, Starling JJ and Dantzig AH, Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. *Int J Cancer* **103**(1): 121-5, 2003.
 99. Stewart A, Steiner J, Mellows G, Laguda B, Norris D and Bevan P, Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. *Clin Cancer Res* **6**(11): 4186-91, 2000.
 100. Ford JM, Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. *Eur J Cancer* **32A**(6): 991-1001, 1996.
 101. Wang RB, Kuo CL, Lien LL and Lien EJ, Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. *J Clin Pharm Ther* **28**(3): 203-28, 2003.

102. Bates SF, Chen C, Robey R, Kang M, Figg WD and Fojo T, Reversal of multidrug resistance: lessons from clinical oncology. *Novartis Found Symp* **243**: 83-96; discussion 96-102, 180-5, 2002.
103. Burg D, Wielinga P, Zelcer N, Saeki T, Mulder GJ and Borst P, Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. *Mol Pharmacol* **62**(5): 1160-6, 2002.
104. Cullen KV, Davey RA and Davey MW, Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. *Biochem Pharmacol* **62**(4): 417-24, 2001.
105. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A and Fardel O, The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. *Br J Pharmacol* **132**(3): 778-84, 2001.
106. Perloff MD, Von Moltke LL, Marchand JE and Greenblatt DJ, Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. *J Pharm Sci* **90**(11): 1829-37, 2001.
107. Suzuki T, Nishio K and Tanabe S, The MRP family and anticancer drug metabolism. *Curr Drug Metab* **2**(4): 367-77, 2001.
108. Tan B, Piwnica-Worms D and Ratner L, Multidrug resistance transporters and modulation. *Curr Opin Oncol* **12**(5): 450-8, 2000.
109. de Bruin M, Miyake K, Litman T, Robey R and Bates SE, Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. *Cancer Lett* **146**(2): 117-26, 1999.
110. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O and Schinkel AH, Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. *Cancer Res* **63**(6): 1339-44, 2003.
111. Kruijtzter CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM and Schellens JH, Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. *J Clin Oncol* **20**(13): 2943-50, 2002.
112. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH and Schinkel AH, Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. *J Natl Cancer Inst* **92**(20): 1651-6, 2000.
113. Rabindran SK, Ross DD, Doyle LA, Yang W and Greenberger LM, Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. *Cancer Res* **60**(1): 47-50, 2000.
114. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T and Greenberger LM, Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. *Cancer Res* **58**(24): 5850-8, 1998.
115. Gupta A, Zhang Y, Unadkat JD and Mao Q, HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). *J Pharmacol Exp Ther* **310**(1): 334-41, 2004.
116. Lin JK L-SS, Mechanism of cancer chemopreventive by curcumin. *Proc Natl Sci Counc ROC (B)* **15**: 59-66, 2001.

117. Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka S and Minami A, Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. *J Biol Chem* **277**(10): 7865-74, 2002.
118. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB and Fini ME, Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. *J Biol Chem* **275**(14): 10405-12, 2000.
119. Lin LI, Ke YF, Ko YC and Lin JK, Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. *Oncology* **55**(4): 349-53, 1998.
120. Yokoo T and Kitamura M, Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. *Am J Physiol* **270**(1 Pt 2): F123-30, 1996.
121. Lin JK, Pan MH and Lin-Shiau SY, Recent studies on the biofunctions and biotransformations of curcumin. *Biofactors* **13**(1-4): 153-8, 2000.
122. Pan MH, T.M. Huang, and J.K. Lin, Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metab Dispos* **27**(4): 482-94, 1999.
123. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res* **21**(4B): 2895-900, 2001.
124. Eigner D and Scholz D, Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. *J Ethnopharmacol* **67**(1): 1-6, 1999.
125. Holder M, Plummer L and J. R, The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. *Xenobiotica* **8**: 761-768, 1978.
126. Shankar TN, Shantha NV, Ramesh HP, Murthy IA and Murthy VS, Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. *Indian J Exp Biol* **18**(1): 73-5, 1980.
127. VS G, Turmeric chemistry, technology and quality. *CRV Rev Food Sci Nutr* **12**: 199-301, 1980.
128. Limtrakul P, Anuchapreeda S and Buddhasukh D, Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. *BMC Cancer* **4**(1): 13, 2004.
129. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV and Limtrakul P, Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). *Cancer Chemother Pharmacol*: 1-13, 2005.
130. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan I and Gottesman MM, Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. *J Biol Chem* **261**(17): 7762-70, 1986.

131. Cardarelli CO, Aksentijevich I, Pastan I and Gottesman MM, Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. *Cancer Res* **55**(5): 1086-91, 1995.
132. Clark R, Currier, S., Kaplan, O., Lovelace, E., Boulay, V., Gottesman, M.M., Dickson, R., Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. *J. Natl. Cancer Inst* **84**: 1506-12, 1992.
133. Muller M, Yong M, Peng XH, Petre B, Arora S and Ambudkar SV, Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). *Biochemistry* **41**(31): 10123-32, 2002.
134. Sauna ZE, Muller M, Peng XH and Ambudkar SV, Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). *Biochemistry* **41**(47): 13989-4000, 2002.
135. Ambudkar SV, Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. *Methods Enzymol* **292**: 504-14, 1998.
136. Schaffner W and Weissmann C, A rapid, sensitive, and specific method for the determination of protein in dilute solution. *Anal Biochem* **56**(2): 502-14, 1973.
137. Kerr KM, Sauna ZE and Ambudkar SV, Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. *J Biol Chem* **276**(12): 8657-64, 2001.
138. Sauna ZE, Nandigama K and Ambudkar SV, Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. *J Biol Chem* **279**(47): 48855-64, 2004.
139. Dey S, Ramachandra M, Pastan I, Gottesman MM and Ambudkar SV, Photoaffinity labeling of human P-glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding. *Methods Enzymol* **292**: 318-28, 1998.
140. Debruyne I, Inorganic phosphate determination: colorimetric assay based on the formation of a rhodamine B-phosphomolybdate complex. *Analytical Biochemistry* **130**: 454-460, 1983.
141. Gozalez-Romo SS-NaMG-R, A modified colorimetric method for the determination of orthophosphate in the presence of high ATP concentrations. *Analytical Biochemistry* **200**: 235-238, 1992.
142. Greenberger LM, Identification of drug interaction sites in P-glycoprotein. *Methods Enzymol* **292**: 307-17, 1998.
143. Peer M, Csaszar E, Vorlaufer E, Kopp S and Chiba P, Photoaffinity labeling of P-glycoprotein. *Mini Rev Med Chem* **5**(2): 165-72, 2005.
144. Sauna ZE and Ambudkar SV, Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. *J Biol Chem* **276**(15): 11653-61, 2001.
145. Sauna ZE, Andrus MB, Turner TM and Ambudkar SV, Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein

- (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. *Biochemistry* **43**(8): 2262-71, 2004.
146. Plouzek CA, Ciolino HP, Clarke R and Yeh GC, Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. *Eur J Cancer* **35**(10): 1541-5, 1999.
147. Jodoin J, Demeule M and Beliveau R, Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. *Biochim Biophys Acta* **1542**(1-3): 149-59, 2002.
148. Chowdhury H WS, Saxena VS, Isolation, characterization and insect growth inhibitory activity of major turmeric constituents and their derivatives against *Schistocerca gregaria* (Forsk) and *Dysdercus koenigii* (Walk). *Pest Management Science* **56**: 1086-92, 2000.
149. Yoshikawa M, Ito A, Ishikawa T and Ikegami Y, [Drug resistance mediated by ABC transporters]. *Gan To Kagaku Ryoho* **31**(1): 1-6, 2004.
150. Sarkadi B, Price EM, Boucher RC, Germann UA and Scarborough GA, Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. *J Biol Chem* **267**(7): 4854-8, 1992.
151. Sauna ZE, Peng XH, Nandigama K, Tekle S and Ambudkar SV, The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). *Mol Pharmacol* **65**(3): 675-84, 2004.
152. Homolya L, Varadi A and Sarkadi B, Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. *Biofactors* **17**(1-4): 103-14, 2003.
153. Aouali N, Eddabra L, Macadre J and Morjani H, Immunosuppressors and reversion of multidrug-resistance. *Crit Rev Oncol Hematol*, 2005.
154. Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B, van Zanden JJ, Rietjens IM, van Bladeren PJ and Cnubben NH, Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. *Chem Res Toxicol* **16**(12): 1642-51, 2003.
155. Wu CP, Klokouzas A, Hladky SB, Ambudkar SV and Barrand MA, Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. *Biochem Pharmacol* **70**(4): 500-10, 2005.
156. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B, Pieters R and Sonneveld P, Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). *Leukemia* **16**(5): 833-9, 2002.
157. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F and Sauerbrey A, BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. *Leukemia* **16**(8): 1443-7, 2002.
158. Robey RW, Steadman K, Polgar O and Bates SE, ABCG2-Mediated Transport of Photosensitizers: Potential Impact on Photodynamic Therapy. *Cancer Biol Ther* **4**(2), 2005.

159. Janvilisri T, Shahi S, Venter H, Balakrishnan L and van Veen HW, Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). *Biochem J* **385**(Pt 2): 419-26, 2005.
160. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD, A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc Natl Acad Sci U S A* **95**(26): 15665-70, 1998.
161. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL and Fojo AT, Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. *J Biol Chem* **265**(17): 10073-80, 1990.
162. Ozvegy C, Varadi A and Sarkadi B, Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. *J Biol Chem* **277**(50): 47980-90, 2002.
163. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T and Bates SE, A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). *Biochim Biophys Acta* **1512**(2): 171-82, 2001.
164. Pan MH, Huang TM and Lin JK, Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metab Dispos* **27**(4): 486-94, 1999.
165. Lin JK and Lin-Shiau SY, Mechanisms of cancer chemoprevention by curcumin. *Proc Natl Sci Counc Repub China B* **25**(2): 59-66, 2001.
166. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP and Gescher AJ, Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. *Cancer Epidemiol Biomarkers Prev* **11**(1): 105-11, 2002.
167. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP and Gescher A, Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. *Cancer Res* **61**(3): 1058-64, 2001.
168. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB, Internal duplication and homology with bacterial transport proteins in the *mdr1* (P-glycoprotein) gene from multidrug-resistant human cells. *Cell* **47**(3): 381-9, 1986.
169. Ueda K CC, Gottesman MM, Pastan I, Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicines, doxorubicine, and vinblastine. *Proc Natl Acad Sci U S A* **84**: 3004-8, 1987.
170. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science* **258**(5088): 1650-4, 1992.
171. Lee CH, Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). *Curr Med Chem Anti-Canc Agents* **4**(1): 43-52, 2004.

172. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I and Gottesman MM, Human multidrug-resistant cell lines: increased *mdr1* expression can precede gene amplification. *Science* **232**(4750): 643-5, 1986.
173. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM and Pastan I, Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. *Proc Natl Acad Sci U S A* **89**(18): 8472-6, 1992.
174. Limtrakul P, Khantamat O and Pintha K, Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. *J Chemother* **17**(1): 86-95, 2005.
175. Tang XQ, Bi H, Feng JQ and Cao JG, Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. *Acta Pharmacol Sin* **26**(8): 1009-16, 2005.
176. Geney R, Ungureanu M, Li D and Ojima I, Overcoming multidrug resistance in taxane chemotherapy. *Clin Chem Lab Med* **40**(9): 918-25, 2002.
177. Romiti N, Tongiani R, Cervelli F and Chieli E, Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. *Life Sci* **62**(25): 2349-58, 1998.
178. Depeille P, Cuq P, Mary S, Passagne I, Evrard A, Cupissol D and Vian L, Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. *Mol Pharmacol* **65**(4): 897-905, 2004.
179. Bielak-Mijewska A, Piwocka K, Magalska A and Sikora E, P-glycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells. *Cancer Chemother Pharmacol* **53**(2): 179-85, 2004.
180. Harbottle A, Daly AK, Atherton K and Campbell FC, Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. *Int J Cancer* **92**(6): 777-83, 2001.
181. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM and Pastan I, Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. *Biochemistry* **37**(14): 5010-9, 1998.
182. Greenberger LM, Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. *J Biol Chem* **268**(15): 11417-25, 1993.
183. Wortelboer HM, Usta M, van Zanden JJ, van Bladeren PJ, Rietjens IM and Cnubben NH, Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha,beta-unsaturated carbonyl compounds. *Biochem Pharmacol* **69**(12): 1879-90, 2005.
184. Iersel ML, Ploemen JP, Struik I, van Amersfoort C, Keyzer AE, Schefferlie JG and van Bladeren PJ, Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. *Chem Biol Interact* **102**(2): 117-32, 1996.
185. Zaman GJ, Cnubben NH, van Bladeren PJ, Evers R and Borst P, Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. *FEBS Lett* **391**(1-2): 126-30, 1996.

186. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL and Caplan MJ, Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. *Science* **304**(5670): 600-2, 2004.
187. Saadane A, Soltys J and Berger M, Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. *J Allergy Clin Immunol* **115**(2): 405-11, 2005.
188. Berger AL, Ikuma M and Welsh MJ, Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. *Proc Natl Acad Sci U S A* **102**(2): 455-60, 2005.
189. Berger AL, Randak CO, Ostedgaard LS, Karp PH, Vermeer DW and Welsh MJ, Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl⁻ channel activity. *J Biol Chem* **280**(7): 5221-6, 2005.
190. Soltys J, Bonfield T, Chmiel J and Berger M, Functional IL-10 deficiency in the lung of cystic fibrosis (cftr^{-/-}) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. *J Immunol* **168**(4): 1903-10, 2002.
191. Araujo CC and Leon LL, Biological activities of *Curcuma longa* L. *Mem Inst Oswaldo Cruz* **96**(5): 723-8, 2001.
192. Nakamura Y, Ohto Y, Murakami A, Osawa T and Ohigashi H, Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivo. *Jpn J Cancer Res* **89**(4): 361-70, 1998.
193. Sugiyama Y, Kawakishi S and Osawa T, Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. *Biochem Pharmacol* **52**(4): 519-25, 1996.
194. Osawa T and Kato Y, Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. *Ann N Y Acad Sci* **1043**: 440-51, 2005.
195. Atsumi T, Fujisawa S and Tonosaki K, Relationship between intracellular ROS production and membrane mobility in curcumin- and tetrahydrocurcumin-treated human gingival fibroblasts and human submandibular gland carcinoma cells. *Oral Dis* **11**(4): 236-42, 2005.
196. Pari L and Amali DR, Protective role of tetrahydrocurcumin (THC) an active principle of turmeric on chloroquine induced hepatotoxicity in rats. *J Pharm Pharm Sci* **8**(1): 115-23, 2005.
197. Girija CR, Begum NS, Syed AA and Thiruvengatam V, Hydrogen-bonding and C-H...pi interactions in 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione (tetrahydrocurcumin). *Acta Crystallogr C* **60**(Pt 8): o611-3, 2004.
198. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM and Dickson RB, Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. *J Natl Cancer Inst* **84**(19): 1506-12, 1992.
199. Hong J, Lambert JD, Lee SH, Sinko PJ and Yang CS, Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. *Biochem Biophys Res Commun* **310**(1): 222-7, 2003.
200. Borst P and Schinkel AH, What have we learnt thus far from mice with disrupted P-glycoprotein genes? *Eur J Cancer* **32A**(6): 985-90, 1996.

201. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA and Sartorelli AC, Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. *Cancer Res* **57**(23): 5238-42, 1997.
202. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P and Borst P, Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. *Nat Med* **3**(11): 1275-9, 1997.
203. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD and Sorrentino BP, Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. *Proc Natl Acad Sci U S A* **99**(19): 12339-44, 2002.
204. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA and Gautam SC, Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. *Mol Cancer Ther* **3**(7): 803-12, 2004.
205. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M and Aggarwal BB, Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. *Blood* **103**(8): 3175-84, 2004.
206. Duvoix A, Morceau F, Delhalle S, Schmitz M, Schnekenburger M, Galteau MM, Dicato M and Diederich M, Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. *Biochem Pharmacol* **66**(8): 1475-83, 2003.
207. Anto RJ, Venkatraman M and Karunakaran D, Inhibition of NF-kappaB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance. *J Biol Chem* **278**(28): 25490-8, 2003.
208. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M and Cheng AL, Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. *Biochem Pharmacol* **63**(9): 1709-16, 2002.
209. Soler AP, Marano CW, Bryans M, Miller RD, Garulacan LA, Mauldin SK, Stamato TD and Mullin JM, Activation of NF-kappaB is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosis. *Eur J Cell Biol* **78**(1): 56-66, 1999.
210. Bharti AC, Donato N, Singh S and Aggarwal BB, Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. *Blood* **101**(3): 1053-62, 2003.
211. Hour TC, Chen J, Huang CY, Guan JY, Lu SH and Pu YS, Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. *Prostate* **51**(3): 211-8, 2002.

212. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H and Haga N, Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. *Cancer Sci* **94**(1): 15-21, 2003.
213. Awasthi S, Pandya U, Singhal SS, Lin JT, Thiviyanathan V, Seifert WE, Jr., Awasthi YC and Ansari GA, Curcumin-glutathione interactions and the role of human glutathione S-transferase P1-1. *Chem Biol Interact* **128**(1): 19-38, 2000.
214. Singhal SS, Awasthi S, Pandya U, Piper JT, Saini MK, Cheng JZ and Awasthi YC, The effect of curcumin on glutathione-linked enzymes in K562 human leukemia cells. *Toxicol Lett* **109**(1-2): 87-95, 1999.
215. Singh SV, Hu X, Srivastava SK, Singh M, Xia H, Orchard JL and Zaren HA, Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. *Carcinogenesis* **19**(8): 1357-60, 1998.
216. Piper JT, Singhal SS, Salameh MS, Torman RT, Awasthi YC and Awasthi S, Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. *Int J Biochem Cell Biol* **30**(4): 445-56, 1998.
217. van Iersel ML, Ploemen JP, Lo Bello M, Federici G and van Bladeren PJ, Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. *Chem Biol Interact* **108**(1-2): 67-78, 1997.
218. Oetari S, Sudibyo M, Commandeur JN, Samhoedi R and Vermeulen NP, Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. *Biochem Pharmacol* **51**(1): 39-45, 1996.